"The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use has recommended marketing authorization for two octocog alfa products (Iblias and Kovaltry, Bayer Pharma AG) for treatment and prevention of blee"...
A few cases of acute overdosage with AMICAR (aminocaproic acid) administered intravenously have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. One patient with a history of brain tumor and seizures experienced seizures after receiving an 8 gram bolus injection of AMICAR (aminocaproic acid) . The single dose of AMICAR (aminocaproic acid) causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while acute renal failure has been reported following a dose of 12 grams.
The intravenous and oral LD50 of AMICAR (aminocaproic acid) were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-clonic convulsions were observed in dogs and mice.
No treatment for overdosage is known, although evidence exists that AMICAR (aminocaproic acid) is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of AMICAR (aminocaproic acid) is markedly decreased in patients with severe renal failure.
AMICAR (aminocaproic acid) should not be used when there is evidence of an active intravascular clotting process.
When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering AMICAR (aminocaproic acid) .
The following tests can be applied to differentiate the two conditions:
- Platelet count is usually decreased in DIC but normal in primary fibrinolysis.
- Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis.
- The euglobulin clot Iysis test is abnormal in primary fibrinolysis but normal in DIC.
AMICAR (aminocaproic acid) must not be used in the presence of DIC without concomitant heparin.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/11/2009
Additional Amicar Information
Amicar - User Reviews
Amicar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.